Chief Executive David Ricks told then-UK Health Secretary Victoria Atkins last December that the company’s new Alzheimer’s ...

The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...

One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

Eli Lilly has finally made enough supply of its popular medicine tirzepatide to meet soaring demand, which should help the ...

The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...

Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...

Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...